Pharmaceutical
company Incyte on Monday announced that it has halted
developed on its experimental HIV nucleoside reverse
transcriptase inhibitor DFC, formerly known as
Reverset, because the drug boosted risks for
pancreatic inflammation. Researchers noted an increased
level of grade 4 hyperlipasemia, a marker of
pancreatic inflammation, in the Phase II-b study.
Based on the study findings, Incyte announced it has halted
enrollment in the clinical trial and will begin working with
the Food and Drug Administration to find alternative
treatments for the study participants who have
drug-resistant virus and few other treatment options.
(The Advocate)
Charlie Kirk DID say stoning gay people was the 'perfect law' — and these other heinous quotes